{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:39:07Z","timestamp":1740109147333,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Beijing High-level Health Personnel Training Program","award":["(2015-3-090)"],"award-info":[{"award-number":["(2015-3-090)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00404-019-05318-2","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T15:04:59Z","timestamp":1569942299000},"page":"1399-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter?"],"prefix":"10.1007","volume":"300","author":[{"given":"Jianbin","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0019-092X","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haili","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"issue":"6","key":"5318_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"S3","key":"5318_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.7314\/APJCP.2016.17.S3.43","volume":"17","author":"Mahshid Ghoncheh","year":"2016","unstructured":"Ghoncheh Mahshid, Pournamdar Zahra, Salehiniya Hamid (2016) Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 17(S3):43\u201346","journal-title":"Asian Pac J Cancer Prev"},{"issue":"26","key":"5318_CR3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJM198812293192601","volume":"319","author":"Early Breast Cancer Trialists Collaborative Group","year":"1988","unstructured":"Early Breast Cancer Trialists Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319(26):1681\u20131692","journal-title":"N Engl J Med"},{"issue":"8","key":"5318_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1056\/NEJM198902233200802","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 320(8):479\u2013484","journal-title":"N Engl J Med"},{"issue":"3","key":"5318_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"EP Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN et al (2005) American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619\u2013629","journal-title":"J Clin Oncol"},{"issue":"1","key":"5318_CR6","first-page":"32","volume":"55","author":"T Nagyk\u00e1lnai","year":"2011","unstructured":"Nagyk\u00e1lnai T, Landherr L, M\u00e9sz\u00e1ros E (2011) Aromatase inhibitors and arthralgia. Magy Onkol 55(1):32\u201339","journal-title":"Magy Onkol"},{"issue":"5","key":"5318_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5301\/tj.5000376","volume":"101","author":"L Moscetti","year":"2015","unstructured":"Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N, Frittelli P, Massari A et al (2015) Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 101(5):469\u2013473","journal-title":"Tumori"},{"issue":"1","key":"5318_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/01443610400024740","volume":"25","author":"GC Rieck","year":"2005","unstructured":"Rieck GC, Freites ON, Williams S (2005) Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol 25(1):39\u201341","journal-title":"J Obstet Gynaecol"},{"issue":"4","key":"5318_CR9","first-page":"357","volume":"30","author":"F Neri","year":"2009","unstructured":"Neri F, Maggino T (2009) Surveillance of endometrial pathologies, especially for endometrial cancer, of breast cancer patients under tamoxifen treatment. Eur J Gynaecol Oncol 30(4):357\u2013360","journal-title":"Eur J Gynaecol Oncol"},{"issue":"4","key":"5318_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jnci\/djx214","volume":"110","author":"J Lortet-Tieulent","year":"2018","unstructured":"Lortet-Tieulent J, Ferlay J, Bray F, Jemal A (2018) International patterns and trends in endometrial cancer incidence, 1978\u20132013. J Natl Cancer Inst 110(4):354\u2013361","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"5318_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","volume":"379","author":"PA Francis","year":"2018","unstructured":"Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, L\u00e1ng I et al (2018) Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 379(2):122\u2013137","journal-title":"N Engl J Med"},{"issue":"9","key":"5318_CR12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/bjs.10899","volume":"105","author":"CA Fleming","year":"2018","unstructured":"Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, Prichard RS et al (2018) Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg 105(9):1098\u20131106","journal-title":"Br J Surg"},{"issue":"1","key":"5318_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1871520614666141020153543","volume":"15","author":"AP Romagnolo","year":"2015","unstructured":"Romagnolo AP, Romagnolo DF, Selmin OI (2015) BRCA1 as target for breast cancer prevention and therapy. Anticancer Agents Med Chem 15(1):4\u201314","journal-title":"Anticancer Agents Med Chem"},{"key":"5318_CR14","first-page":"101","volume":"10","author":"A Bellazzo","year":"2018","unstructured":"Bellazzo A, Sicari D, Valentino E, Del Sal G, Collavin L (2018) Complexes formed by mutant p53 and their roles in breast cancer. Breast Cancer (Dove Med Press) 10:101\u2013112","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"1","key":"5318_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-015-3665-z","volume":"165","author":"J Ngeow","year":"2017","unstructured":"Ngeow J, Sesock K, Eng C (2017) Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat 165(1):1\u20138","journal-title":"Breast Cancer Res Treat"},{"key":"5318_CR16","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2147\/DDDT.S84437","volume":"9","author":"Z Suba","year":"2015","unstructured":"Suba Z (2015) DNA stabilization by the upregulation of estrogen signaling in BRCA gene mutation carriers. Drug Des Devel Ther 9:2663\u20132675","journal-title":"Drug Des Devel Ther"},{"key":"5318_CR17","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1128\/MCB.22.12.4280-4292.2002","volume":"22","author":"TK MacLachlan","year":"2002","unstructured":"MacLachlan TK, Takimoto R, El-Deiry WS (2002) BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 22:4280\u20134292","journal-title":"Mol Cell Biol"},{"issue":"4","key":"5318_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5603\/GP.a2017.0040","volume":"88","author":"M Bulsa","year":"2017","unstructured":"Bulsa M, Urasi\u0144ska E (2017) Triple negative endometrial cancer. Ginekol Pol 88(4):212\u2013214","journal-title":"Ginekol Pol"},{"issue":"9","key":"5318_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1593\/neo.05256","volume":"7","author":"BD Jeffy","year":"2005","unstructured":"Jeffy BD, Hockings JK, Kemp MQ, Morgan SS, Hager JA, Beliakoff J et al (2005) An estrogen receptor-alpha\/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun\/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia 7(9):873\u2013882","journal-title":"Neoplasia"},{"key":"5318_CR20","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1128\/MCB.20.20.7450-7459.2000","volume":"20","author":"P Arizti","year":"2000","unstructured":"Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T, Aaronson SA, Lee SW (2000) Tumor suppressor p53 is required to modulate BRCA1 expression. Mol Cell Biol 20:7450\u20137459","journal-title":"Mol Cell Biol"},{"issue":"11","key":"5318_CR21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","volume":"2","author":"CA Shu","year":"2016","unstructured":"Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA et al (2016) Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2(11):1434\u20131440","journal-title":"JAMA Oncol"},{"issue":"4","key":"5318_CR22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ijc.25395","volume":"128","author":"SX Liang","year":"2011","unstructured":"Liang SX, Pearl M, Liang S, Xiang L, Jia L, Yang B et al (2011) Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Int J Cancer 128(4):763\u2013770","journal-title":"Int J Cancer"},{"issue":"1","key":"5318_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ygyno.2008.08.035","volume":"112","author":"AE Bland","year":"2009","unstructured":"Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A et al (2009) Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol 112(1):150\u2013154","journal-title":"Gynecol Oncol"},{"key":"5318_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.AOG.0000131620.67911.03","volume":"104","author":"BM Slomovitz","year":"2004","unstructured":"Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH (2004) Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol 104:255\u2013260","journal-title":"Obstet Gynecol"},{"issue":"4","key":"5318_CR25","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3892\/ol.2013.1156","volume":"5","author":"M Le Donne","year":"2013","unstructured":"Le Donne M, Alibrandi A, Ciancimino L, Azzerboni A, Chiofalo B, Triolo O (2013) Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings. Oncol Lett 5(4):1305\u20131310","journal-title":"Oncol Lett"},{"issue":"1","key":"5318_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/obr.12229","volume":"16","author":"S O'Neill","year":"2015","unstructured":"O'Neill S, O'Driscoll L (2015) Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 16(1):1\u201312","journal-title":"Obes Rev"},{"key":"5318_CR27","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135\u20131141","journal-title":"Lancet Oncol"},{"key":"5318_CR28","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","volume":"12","author":"MM Regan","year":"2011","unstructured":"Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1\u201398 randomised clinical trial at 81 years median follow-up. Lancet Oncol 12:1101\u20131108","journal-title":"Lancet Oncol"},{"key":"5318_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:8\u201330","journal-title":"Ann Oncol"},{"key":"5318_CR30","unstructured":"National Comprehensive Cancer Network (NCCN) (2015) Clinical Practice Guidelines in Oncology. Breast Cancer, Version 3. [DB\/OL]. \n                    http:\/\/www.nccn.org"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05318-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-019-05318-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05318-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T23:34:18Z","timestamp":1601422458000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-019-05318-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["5318"],"URL":"https:\/\/doi.org\/10.1007\/s00404-019-05318-2","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"type":"print","value":"0932-0067"},{"type":"electronic","value":"1432-0711"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"assertion":[{"value":"5 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}